Bayer Inc. is merging with Takeda Pharmaceutical. Bayer has global offices in Germany and over 300 companies in 74 countries, with a mission of "Science For A Better Life." Takeda was established in 1781 in Japan and has over 38,000 employees and 260,000 shareholders. It is involved in R&D, production, distribution and marketing of drugs. The merger justification includes Takeda and Bayer's past work together and cultural alignment. The estimated cost is $36 million with a breakeven point of $2.2 million in sales annually and a payback period of 5 years. Protection strategies include ownership documents, access restrictions, exit planning, insurance, and an IPO exit